Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Accured Expenses (2022 - 2025)

Corvus Pharmaceuticals has reported Change in Accured Expenses over the past 4 years, most recently at $765000.0 for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $765000.0 for Q4 2025, up 256.12% from a year ago — trailing twelve months through Dec 2025 was $2.8 million (up 1226.94% YoY), and the annual figure for FY2025 was $2.8 million, up 1226.94%.
  • Change in Accured Expenses for Q4 2025 was $765000.0 at Corvus Pharmaceuticals, up from $708000.0 in the prior quarter.
  • Over the last five years, Change in Accured Expenses for CRVS hit a ceiling of $2.2 million in Q3 2022 and a floor of -$1.9 million in Q1 2023.
  • Median Change in Accured Expenses over the past 4 years was $99500.0 (2023), compared with a mean of -$37187.5.
  • Biggest five-year swings in Change in Accured Expenses: crashed 401.04% in 2023 and later soared 895.51% in 2025.
  • Corvus Pharmaceuticals' Change in Accured Expenses stood at -$1.0 million in 2022, then soared by 42.37% to -$589000.0 in 2023, then increased by 16.81% to -$490000.0 in 2024, then soared by 256.12% to $765000.0 in 2025.
  • The last three reported values for Change in Accured Expenses were $765000.0 (Q4 2025), $708000.0 (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.